Skip to content

Effect of Two Different Rye Bread Types in Irritable Bowel Syndrome

Effects of Traditional and Low-FODMAP Rye Bread in Irritable Bowel Syndrome.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02161120
Enrollment
87
Registered
2014-06-11
Start date
2014-04-30
Completion date
Unknown
Last updated
2015-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Keywords

IBS, irritable bowel syndrome, functional gastrointestinal disorder, diet, bread, rye, FODMAP, microbiota

Brief summary

The purpose of this study is to evaluate if low-FODMAP (Fermented Oligo-, Di-, Monosaccharides And Polyols) rye bread is better tolerated in irritable bowel syndrome than commonly available traditional rye bread higher in FODMAP carbohydrates. The study also aims to investigate patients' compliance to rye bread regimen, potential changes is gut microbiota and hydrogen production during the test periods (a marker of large bowel fermentation of poorly absorbed carbohydrates).

Interventions

OTHERTraditional Finnish rye bread
OTHERLow FODMAP rye bread

Sponsors

Oy Karl Fazer Ab
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* IBS according to Rome III criteria. Accepted sub-types include IBS-M, IBS-D and IBS-U * Age 18-65 years * Willing to use rye bread daily during the study periods

Exclusion criteria

* IBS-C (constipation dominant) * Celiac disease * IBD * Major gastrointestinal operations like bowel gastric resection * Non-treated hypo- or hyperthyroidism * Alcoholism, severe depression, dementia, cancer or other diseases likely to severly impair the participants ability to conclude the protocol * Regular (almost daily) use of NSAIDs, antibiotics or lactulose * Linaclotide and other prescription medicines targeted specifically to IBS * Pregnancy and lactation * Follows currently strict low-FODMAP diet

Design outcomes

Primary

MeasureTime frame
Change is IBS symptoms by using IBS-SSS questionaire4 weeks

Secondary

MeasureTime frame
IBS quality of life by using IBS QoL questionnaire4 weeks
Changes in specific IBS symptoms measured by 100 mm VAS scale4 weeks
Changes is intestinal microbiota evaluated by fecal samples4 weeks
Changes in hydrogen excretion evaluated by 6 hours breath test after standard rye bread breakfast4 weeks

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026